The University of Texas MD Anderson Cancer Center | Strategic Alliance Partners

Timothy Yap, MBBS, PhD, FRCP, discusses the rationale for investigating saruparib in advanced solid tumors, such as prostate cancer with genetic mutations.

Experts from across oncology specialties discuss the abstracts and presentations they are most looking forward to seeing at the 2024 ASCO Annual Meeting.

Timothy Yap, MBBS, PhD, FRCP, discusses encouraging data seen with the first-in-class PARP1 selective inhibitor saruparib in solid tumors and how the agent is being further investigated.

Debu Tripathy, MD, discusses the current state of HER2-positive breast cancer treatment.

Debu Tripathy, MD, discusses real-world strategies for CDK4/6 inhibitor use and the importance of HER2 testing in HER2-positive metastatic breast cancer.

Parul N Barry, MD, discusses the integration of partial breast irradiation therapy into the treatment of patients with breast cancer.

Ramez Kouzy, MD, discusses efforts to improve knowledge of the use of AI in radiation oncology through the creation of an online repository.

James Ignatz-Hoover, MD, PhD, discusses the current arsenal of FDA-approved bispecific antibodies in multiple myeloma.

Naval G. Daver, MD, highlights ongoing research efforts in relapsed/refractory AML, including combination regimens and pathways targeted by novel agents.

The panel concludes with perspectives on the future of treatment for patients with colorectal cancer, including unmet needs in the disease space.

Núria Agustí Garcia, MD, discusses the mapping of sentinel lymph nodes in early-stage ovarian cancer.

Clinical insights on the roles of various members within a multidisciplinary team involved in the care of patients with colorectal cancer.

Experts on colorectal cancer discuss the treatment decision-making process, highlighting the safety profiles of fruquintinib and regorafenib.

Naval G. Daver, MD, discusses the future of targeted therapy development for patients with acute myeloid leukemia.

Elias Jabbour, MD, discusses outcomes from the phase 3 PhALLCON trial in patients with Ph-positive acute lymphoblastic leukemia.

Debu Tripathy, MD, discusses the current state of the HER2-positive breast cancer treatment paradigm.

Scott Kopetz, MD, PhD, FACP, discusses the potential FDA approval of adagrasib in combination with cetuximab in KRAS G12C-mutatated colorectal cancer.

Samer A. Srour, MB ChB, MS, explains the significance of early safety and efficacy data with CTX130 in CD70-expressing clear cell renal cell carcinoma.

Scott Kopetz, MD, PhD, FACP, discusses using adagrasib plus cetuximab in patients with metastatic colorectal cancer harboring KRAS G12C mutations.

James Ignatz-Hoover, MD, PhD, discusses the implications of utilizing blinatumomab to treat acute lymphoblastic leukemia.

Eric K. Singhe, MD, of The University of Texas MD Anderson Cancer Center, discusses the journey of non–smell cell lung cancer treatment through mentorship, advocacy, and more.

Samer A. Srour, MB ChB, MS, discusses the investigation of the allogeneic CAR T-cell therapy CTX131 in advanced clear cell renal cell carcinoma.

Debu Tripathy, MD, highlights the potential role and significance of vepdegestrant in pretreated ER-positive/HER2-negative breast cancer.

Christina L. Roland, MD, MS, FACS, discusses a study of neoadjuvant immune-checkpoint blockade in retroperitoneal dedifferentiated liposarcoma.

Naomi Adjei, MD, MPH, MSEd, discusses an analysis of the cost-effectiveness of opportunistic salpingectomy for the primary prevention of ovarian cancer.

Nizar M. Tannir, MD, FACP, discusses unmet needs for patients with rare kidney tumors and how these needs may be addressed in the future.

Michael Leung, PharmD, presents the case of a 57-year-old man with cecal colon adenocarcinoma and provides his initial thoughts, particularly on adverse event management.

Focusing on the treatment of patients receiving regorafenib, the panel details the management of common adverse events, prophylaxis strategies, and the roles of members within a multidisciplinary team.

Samer A. Srour, MB ChB, MS, discusses toxicities associated with CTX130 in advanced clear cell renal cell carcinoma.

Samer A. Srour, MB ChB, MS, discusses the utility of the CAR T-cell therapy CTX130 and unmet needs in advanced clear cell renal cell carcinoma.